Clinical trials: HER2 Positive
HER2-positive Carcinoma, HER2-positive Primary Malignancy
Imaging With a New Agent That Finds a Cancer Protein Called HER2
The purpose of this study is to test if an imaging agent called Zr-DFO-pertuzumab that finds HER2 proteins can be used to take pictures of HER2-positive cancer.
- Trial name
- NCT03109977
- Testing
- Zr-DFO-pertuzumab PET/CT
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumors, Breast Cancer
AT13387 in Adults With Refractory Solid Tumors
Background: The experimental drug AT13387 has been shown to have some anticancer effects against tumor cells by blocking a protein that affects other proteins inside certain cancer cells, and helps to prevent the cancer cells…
- Trial name
- NCT01246102
- Testing
- AT13387
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
TN ER-/PR-/HER2- Breast Cancer, Triple Negative Breast Cancer
Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
This is a feasibility study to gain preliminary information regarding whether breast imaging with or without a core needle biopsy after neoadjuvant chemotherapy (NAC) but before surgery can accurately predict complete pathologic…
- Conditions
- TN ER-/PR-/HER2- Breast Cancer, Triple Negative Breast Cancer, HER2-positive Breast Cancer, ERany/PRany/HER2+ Breast Cancer
- Trial name
- NCT03981705
- Testing
- Standard Trimodality Breast Imaging
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
HER2-positive Breast Cancer
Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag
Ado-trastuzumab emtansine (T-DM1) demonstrates favorable efficacy in breast cancer treatment but is frequently associated with thrombocytopenia.
- Trial name
- NCT07198672
- Testing
- Herombopag
- Volunteers
- 45 people
- Sponsor
- Zhenzhen Liu
Solid Tumors
Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors
A tolerance, safety and pharmacokinetic ascending dose phase I Study of RC48-ADC administered intravenously to subjects with HER2-positive malignant in advanced malignant solid tumors.
- Trial name
- NCT02881190
- Testing
- RC48-ADC
- Where
- China
- Volunteers
- 57 people
- Sponsor
- RemeGen Co., Ltd.
Breast Neoplasms
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
This is an open-label, single arm, phase II trial to evaluate the efficacy and safety of 500mg Fulvestrant (Faslodex®) in ESR1 mutated postmenopausal women with hormone receptor positive, HER2 negative locally advanced or…
- Trial name
- NCT03202862
- Testing
- Fulvestrant
- Volunteers
- 50 people
- Sponsor
- Fudan University
Breast Neoplasms
A Study of Local Therapy for the Treatment of Brain Metastases From HER2 Positive Breast Cancer
This study aims to show that brain metastases from Human Epidermal Growth Factor Receptor Type 2 (HER2) positive breast cancers are able to be controlled by local therapies, Stereotactic Radiosurgery (SRS) and/or Neurosurgery…
- Trial name
- Local HER-O (NCT02898727)
- Testing
- Local Therapy
- Where
- Australia
- Volunteers
- 25 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Stomach Neoplasms
Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care
BVAC-B is immunotherapeutic vaccine using B-Cell and Monocytes as antigen presenting cell. This study is Open-label, Accelerated titration, Multiple dosing study to evaluate the safety, tolerability, immune response and…
- Trial name
- BVAC-B (NCT03425773)
- Testing
- BVAC-B
- Where
- South Korea
- Volunteers
- 8 people
- Sponsor
- Cellid Co., Ltd.
Early-stage Breast Cancer, Hormone Receptor Positive Tumor
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.
A phase II randomised, open label study of pre-operative endocrine therapy with \& without prometrium in postmenopausal women with early stage breast hormone receptor positive (HR+) human epidermal receptor 2 negative (HER2-)…
- Trial name
- WinPro (NCT03906669)
- Testing
- Letrozole, Letrozole and Prometrium, Tamoxifen and Prometrium
- Where
- Australia
- Volunteers
- 200 people
- Sponsor
- St Vincent's Hospital
Breast Cancer
A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
This is a randomised, double-blind multicenter Phase III study for evaluating the efficacy and safety of pyrotinib in women with early stage high-risk breast cancer after adjuvant trastuzumab.
- Trial name
- NCT03980054
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 2,135 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer
Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole
Postmenopausal women with hormone receptor positive and negative Her2 tumours. Before randomization, the patients will be stratified according to the center, positive nodes (0 vs. 1-3 vs.
- Trial name
- NCT00543127
- Testing
- Fulvestrant, Anastrozole
- Where
- 53 sites in Spain
- Volunteers
- 870 people
- Sponsor
- Spanish Breast Cancer Research Group
HER2 Positive Advanced Solid Tumors
HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors
Chimeric antigen receptor modified T (CAR-T) cell therapy still has multiple difficulties in solid tumors, such as absence of tumor specific antigens, complex immunosuppressive tumor microenvironment, and tumor heterogeneity.
- Trial name
- NCT05681650
- Testing
- HypoSti.CAR-HER2 T cells, Albumin-bound paclitaxel, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Breast Cancer (Early Breast Cancer)
A Prospective, Open-label, Randomized Trial Comparing Switch to A1811 Versus Continued THP Neoadjuvant Therapy After THP Induction in HER2-Positive Breast Cancer
This is a multicenter, open-label, randomized controlled trial. A total of 432 eligible patients with HER2-positive breast cancer will be enrolled after screening.
- Trial name
- SwithADC (NCT07844291)
- Testing
- A1811, THP
- Volunteers
- 432 people
- Sponsor
- Peking University People's Hospital
Breast Neoplasms
A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer
This observational study will evaluate the efficacy, safety, tolerability and participant reported quality of life of trastuzumab (Herceptin) subcutaneous (SC) therapy in participants with HER2-positive early breast cancer in…
- Trial name
- HerSCin (NCT01959386)
- Testing
- Trastuzumab
- Where
- Germany
- Volunteers
- 1,006 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer
The investigators plan to carry out a phase II, open-label, single-arm clinical study of short-course trastuzumab, pertuzumab combined with taxanes in the adjuvant treatment of early HER2-positive breast cancer, to explore…
- Trial name
- NCT05891561
- Testing
- Pertuzumab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Adult Solid Tumor, Adenocarcinoma of the Colon
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
RATIONALE: PD 0332991 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well PD 0332991 works in treating patients with…
- Conditions
- Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor
- Trial name
- NCT01037790
- Testing
- PD-0332991
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known which vaccine is most effective in treating breast cancer.
- Trial name
- NCT00640861
- Testing
- CpG oligodeoxynucleotide, HER-2/neu peptide vaccine, MUC-1 peptide vaccine
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic
Breast Cancer
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
This multi-center, prospective observational study will evaluate the treatment patterns, and the safety in patients with HER2-positive (HER2+) metastatic breast cancer (MBC).
- Trial name
- NCT01615068
- Where
- 142 sites in United States
- Volunteers
- 1,007 people
- Sponsor
- Genentech, Inc.
Breast Cancer, HER2-positive Breast Cancer
Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response
The purpose of this study is to evaluate the feasibility, based on recruitment rate over a 3-year period, of enrolling patients for the omission of post-operative breast radiation following breast conserving surgery and sentinel…
- Trial name
- NCT05371860
- Testing
- Omit breast radiation
- Where
- United States
- Sponsor
- Armando Giuliano
Breast Cancer, HER2-positive Breast Cancer
Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
This study will evaluate the efficacy and non-inferiority of a non-surgical approach for the treatment of patients with locally advanced breast cancer.
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NoCUT-BC (NCT07217990)
- Testing
- Neoadjuvant Chemotherapy, Radiation Therapy, MRI
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Ohio State University Comprehensive Cancer Center